SEMA AUDNCT07772960
Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria expanded, about 17 words
- Study sites: 1 to 2
- Secondary endpoints: details revised at 1 of 3 entries
- Publications: details revised at 1 of 1 entry
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Alcohol use days
Timeframe: 20 weeks
Secondary (3)
Heavy drinking days
Average drinks per drinking day
Obsessive Compulsive Drinking Scale (OCDS) to assess Alcohol craving
Arms and interventions
PlaceboPlacebo comparator
Placebo saline pen administered weekly for 20 weeks
Semaglutide 1.0 mgActive comparator
Semaglutide low dose of 1.0 mg administered weekly over the 20-weeks trial
Semaglutide 2.0 mgActive comparator
Semaglutide high dose 2.0 mg administered weekly over the 20-weeks trial
Other: Placebo
Drugs: Semaglutide 1.0 mg, Semaglutide 2.0 mg
Sites
2 sites in 1 country